Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (GlobeNewswire)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (GlobeNewswire)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (GlobeNewswire)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (GlobeNewswire)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (GlobeNewswire)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
23.10.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6% (GlobeNewswire)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (GlobeNewswire)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (GlobeNewswire)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (GlobeNewswire)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (GlobeNewswire)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (GlobeNewswire)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (GlobeNewswire)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (GlobeNewswire)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (GlobeNewswire)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (GlobeNewswire)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (GlobeNewswire)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (GlobeNewswire)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
10.09.24		Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen (GlobeNewswire)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (GlobeNewswire)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (GlobeNewswire)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (GlobeNewswire)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (GlobeNewswire)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (GlobeNewswire)

Zurück | 1 | 2 | Weiter

Newssuche

Roche Peer Group Nachrichten

22:35		Verluste in New York: Dow Jones-Börsianer treten letztendlich den Rückzug an
22:30		US-Glyphosat-Streit: Bayer zieht vor höchstes US-Gericht - Aktie sinkt
20:04		Schwache Performance in New York: Dow Jones-Börsianer treten am Freitagnachmittag Rückzug an
18:03		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones am Mittag
17:59		Schwacher Wochentag in Zürich: SPI-Börsianer nehmen letztendlich Reißaus
17:59		Anleger in Frankfurt halten sich zurück: TecDAX schlussendlich im freien Fall
16:03		Schwacher Handel: Dow Jones beginnt die Sitzung weit in der Verlustzone

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.04.2025 23:13
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten